Review in Cold Spring Harbor perspectives in biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
6 authors.
Tatsuki Nonomura *Center for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M University, Houston, Texas 77030, USA.
Xiaoxuan Liu *Center for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M University, Houston, Texas 77030, USA.
Megan ChiuCenter for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M University, Houston, Texas 77030, USA.
Zhi TanCenter for Drug Discovery, Department of Pathology & Immunology, Baylor College of Medicine, Houston, Texas 77030, USA.
Tien-Hung LanCenter for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M University, Houston, Texas 77030, USA yubinzhou@tamu.edu tienlan08@tamu.edu.
Yubin ZhouCenter for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M University, Houston, Texas 77030, USA yubinzhou@tamu.edu tienlan08@tamu.edu.
Funding
NanoOptogenetic immunotherapy for B cell lymphomaR01CA232017 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI HAN, GANG, ZHOU, YUBIN · 2019 to 2023
$2.2M
Engineering Smart Antibody-like Protein Scaffolds with precision switchesR01GM144986 · NIGMS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI ZHOU, YUBIN · 2022 to 2025
$1.3M
Synthetic biology toolkit for precise tuning of T cell activityR21AI174606 · NIAID · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI ZHOU, YUBIN · 2023 to 2024
$417k
Optogenetic toolkit for precise control of organellar calcium signalingR21GM145063 · NIGMS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI ZHOU, YUBIN · 2022 to 2023
$413k
Selective targeting of a Rho GTPase mutant for peripheral T cell lymphoma treatmentR21CA277257 · NCI · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI ZHOU, YUBIN · 2023 to 2024
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Developing Optogenetic Approaches to Study Ca · full record | OpenQuestion